Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.55 |
| ▸ | SQLE | Q14534 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16428261 | 0.83 | FNTA (0.57) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL16428263 | 0.83 | FNTA (0.57) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL8816891 | 0.82 | KMT2A (0.64) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL16428591 | 0.81 | FNTA (0.54) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL16428593 | 0.81 | FNTA (0.54) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL11154898 | 0.79 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL14815727 | 0.79 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL10885252 | 0.79 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL11154896 | 0.79 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL10885257 | 0.79 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024254550-A1 | COMPOSITIONS AND METHODS FOR PROMOTING PAYLOAD DELIVERY IN CELLS | NVELOP THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024254544-A2 | COMPOSITIONS AND METHODS FOR PROMOTING PAYLOAD DELIVERY IN CELLS | NVELOP THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20220187282-A1 | CARDIOMYOCYTE PROLIFERATION | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2022-06-16 | — | — | US | disclosed |
| EP-3941471-A1 | CARDIOMYOCYTE PROLIFERATION | The Council of the Queensland Institute of Medical Research (AU) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020186283-A1 | CARDIOMYOCYTE PROLIFERATION | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2020-09-24 | — | — | WO | disclosed |
| EP-3661413-A1 | BIOMARKERS ASSOCIATED WITH PARKINSON'S DISEASE | Cove Bio LLC (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019028106-A1 | BIOMARKERS ASSOCIATED WITH PARKINSON'S DISEASE | COVE BIO LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-1879538-B1 | TOPICAL USE OF TEPRENONE | SEDERMA SA (FR) | 2017-08-02 | — | — | EP | disclosed |
| US-9606125-B2 | Methods of detecting conjugation site-specific and hidden epitope/antigen | LIU CHUNLI (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2556043-B1 | NEW POLYTERPENE TYPE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND TOPICAL USES THEREOF | SEDERMA SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-9383367-B1 | Methods of detecting conjugation site-specific and hidden epitope/antigen | LIU CHUNLI (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015181272-A1 | RAB GERANYLGERANYL TRANSFERASE INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2015-12-03 | — | — | WO | disclosed |
| US-20150241450-A1 | Methods of Detecting Conjugation Site-Specific and Hidden Epitope/Antigen | LIU CHUNLI (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2556043-A2 | NEW POLYTERPENE TYPE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND TOPICAL USES THEREOF | Sederma (FR) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011125040-A2 | NEW POLYTERPENE TYPE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND TOPICAL USES THEREOF | SEDERMA (FR) | 2011-10-13 | — | — | WO | disclosed |
| US-20090214607-A1 | Topical use of teprenone | SEDERMA (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-1879538-A1 | TOPICAL USE OF TEPRENONE | Sederma (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006120646-A1 | TOPICAL USE OF TEPRENONE | SEDERMA (FR) | 2006-11-16 | — | — | WO | disclosed |
| US-6284910-B1 | FARNESYL TRANSFERASE INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214607-A1 | Topical use of teprenone | TEAD2, TEAD3, TERT | KMT2A 4167/4885ALOX15 626/4885MAPT 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.